3 Stocks Surging on November 20, 2023: MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), Fortress Biotech, Inc. (Nasdaq: FBIO), and Safety Shot, Inc. (Nasdaq: SHOT)

On November 20, 2023, the stock market witnessed significant surges in the prices of three companies: MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), Fortress Biotech, Inc. (Nasdaq: FBIO), and Safety Shot, Inc. (Nasdaq: SHOT). Let's take a closer look at these companies and the key developments that have propelled their stocks to new heights.

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) - +44.86%
MIRA Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, made a remarkable leap of +44.86% in its stock price on November 20, 2023. This surge was driven by a groundbreaking announcement: the company entered into an exclusive licensing agreement with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder.

Under this agreement, MIRA Pharmaceuticals secured the exclusive rights in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog. Ketamir-2 is designed to revolutionize the landscape of depressive disorder treatments, offering new hope to individuals suffering from refractory depression and depression with suicidal thoughts.

One of the key advantages of Ketamir-2 is its potential to serve as a take-home alternative to the revolutionary drug Spravato, which currently requires administration under medical observation. This development is poised to bring significant advancements in the treatment of depression and expand the options available to patients.

Furthermore, MIRALOGX extended a $3 million line of credit to MIRA Pharmaceuticals to support the initial development of Ketamir-2. This financial backing underscores the commitment to bringing this innovative treatment to market, further boosting investor confidence and driving the stock price to new heights.

To see what Wall Street is saying about MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) click here: https://investorconsensus.com/stock-ticker?symbol=MIRA

Fortress Biotech, Inc. (Nasdaq: FBIO) - +18.01%
Fortress Biotech, Inc., an innovative biopharmaceutical company, experienced an impressive surge of +18.01% in its stock price. This surge was closely tied to the release of the company's third-quarter 2023 financial results and recent corporate highlights.

In the third quarter of 2023, Fortress reported total consolidated net revenue of $34.8 million, marking a remarkable 100% increase from the previous quarter. This significant growth in revenue is a testament to the company's robust portfolio and its ability to efficiently acquire, develop, and commercialize promising therapeutic products and candidates.

Fortress is also advancing several late-stage clinical assets, with three potential New Drug Application (NDA) and Biologics License Application (BLA) submissions to the FDA expected by the end of 2024. One such submission is for DFD-29, a treatment for rosacea, anticipated around year-end 2023. These promising developments have instilled confidence among investors, driving the stock price higher.

To see what Wall Street is saying about Fortress Biotech, Inc. (Nasdaq: FBIO) click here: https://investorconsensus.com/stock-ticker?symbol=FBIO

Safety Shot, Inc. (Nasdaq: SHOT) - +25.78%
Safety Shot, Inc. witnessed a remarkable surge of +25.78% in its stock price on November 20, 2023. This surge was attributed to the company's announcement of the upcoming West Coast launch of Safety Shot, a revolutionary beverage designed to help people feel better faster by reducing blood alcohol content and boosting clarity.

Safety Shot is the first patented beverage on Earth to offer these unique benefits. It was created by industry experts and validated by research, making it a promising addition to the market. A recent study demonstrated that Safety Shot significantly reduced blood alcohol content (BAC) within 30 minutes, compared to a control group. This groundbreaking finding has generated significant excitement among consumers and investors alike.

Safety Shot is set to be available for retail purchase in the first week of December 2023, and its official launch event is scheduled for December 7th in California. Media, investors, and influencers have been invited to try Safety Shot and meet the company's management, further building anticipation for its market entry.

Additionally, a larger double-blinded placebo-controlled trial is underway, with results expected in December 2023. Positive outcomes from this trial could further bolster Safety Shot's position as a game-changer in the beverage industry.


To see what Wall Street is saying about Safety Shot, Inc. (Nasdaq: SHOT)  click here: https://investorconsensus.com/stock-ticker?symbol=SHOT


In conclusion, the surges in the stock prices of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), Fortress Biotech, Inc. (Nasdaq: FBIO), and Safety Shot, Inc. (Nasdaq: SHOT) on November 20, 2023, are reflective of significant developments and promising prospects within their respective industries. These companies have shown their ability to innovate and capture market attention, making them compelling investment opportunities in the ever-evolving world of healthcare and consumer products. Investors should continue to monitor these companies for further developments and potential growth.